Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

Abstract

The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

1 - 11 . (canceled) 
     
     
         12 . A method of stimulating natural killer (NK) cell activity and/or NK cell proliferation, comprising administering to a subject in need thereof an enteral composition comprising fucosyllactose, wherein the composition is not human milk. 
     
     
         13 . The method according to  claim 12 , wherein subject is an infant HIV patient, elderly and/or oncology patient. 
     
     
         14 . The method according to  claim 12 , wherein the subject is an infant. 
     
     
         15 . The method according to  claim 12 , wherein the composition additionally comprises at least one of beta-galacto-oligosaccharides, fructo-oligosaccharides and uronic acid oligosaccharides. 
     
     
         16 . The method according to  claim 12 , wherein the fucosyllactose is 2′-fucosyllactose. 
     
     
         17 . The method according to  claim 12 , wherein the composition comprises 0.07 to 1 wt % fucosyllactose based on dry weight of the composition. 
     
     
         18 . The method according to  claim 12 , wherein the composition comprises 5 to 50% protein, 15 to 85% digestible carbohydrates and 5 to 50% fat based on total energy. 
     
     
         19 . A method of treating and/or preventing viral infections, comprising administering to a subject in need thereof an enteral composition comprising fucosyllactose, wherein the composition is not human milk. 
     
     
         20 . The method according to  claim 19 , wherein subject is an infant HIV patient, elderly and/or oncology patient. 
     
     
         21 . The method according to  claim 19 , wherein the subject is an infant. 
     
     
         22 . The method according to  claim 19 , wherein the composition additionally comprises at least one of beta-galacto-oligosaccharides, fructo-oligosaccharides and uronic acid oligosaccharides. 
     
     
         23 . The method according to  claim 19 , wherein the fucosyllactose is 2′-fucosyllactose. 
     
     
         24 . The method according to  claim 19 , wherein the composition comprises 0.07 to 1 wt % fucosyllactose based on dry weight of the composition. 
     
     
         25 . The method according to  claim 19 , wherein the composition comprises 5 to 50% protein, 15 to 85% digestible carbohydrates and 5 to 50% fat based on total energy. 
     
     
         26 . A method of enhancing a vaccination response, comprising administering to a subject in need thereof a composition comprising fucosyllactose. 
     
     
         27 . The method according to  claim 26 , wherein subject is an infant HIV patient, elderly and/or oncology patient. 
     
     
         28 . The method according to  claim 26 , wherein the composition additionally comprises at least one of beta-galacto-oligosaccharides, fructo-oligosaccharides and uronic acid oligosaccharides. 
     
     
         29 . The method according to  claim 26 , wherein the fucosyllactose is 2′-fucosyllactose. 
     
     
         30 . The method according to  claim 26 , wherein the composition comprises 0.07 to 1 wt % fucosyllactose based on dry weight of the composition. 
     
     
         31 . The method according to  claim 26 , wherein the composition comprises 5 to 50% protein, 15 to 85% digestible carbohydrates and 5 to 50% fat based on total energy.